Physician profile
Brian Patrick Wall
NPI 1740387406
$5,314.91
in general payments reported to CMS, 2019-2025
28 companies · $122 in 2025
The $122 reported for 2025 was less than what a typical Child & Adolescent Psychiatry provider received nationally (typical 2025 total: $132).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,888 · 2020: $490 · 2021: $306 · 2022: $460 · 2023: $686 · 2024: $364 · 2025: $122.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,172.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,171.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $821.70 | 2019-2024 | Spravato, Invega Sustenna |
| Otsuka America Pharmaceutical, INC. | $796.47 | 2019-2023 | Abilify Asimtufii, Abilify Maintena |
| Alkermes, INC. | $686.74 | 2019-2025 | Lybalvi, Aristada |
| Teva Pharmaceuticals USA, INC. | $532.96 | 2019-2023 | Uzedy, Austedo |
| Sunovion Pharmaceuticals INC. | $353.50 | 2019-2020 | |
| Lundbeck LLC | $340.70 | 2019-2024 | Abilify Maintena |
| Neurocrine Biosciences, INC. | $233.21 | 2019-2023 | Ingrezza |
| Takeda Pharmaceuticals U.S.A., INC. | $221.85 | 2019-2022 | |
| Abbvie INC. | $149.98 | 2021-2024 | Vraylar |
| Supernus Pharmaceuticals, INC. | $147.65 | 2021-2023 | Qelbree |
| Allergan, INC. | $141.75 | 2019-2020 | |
| Shire North American Group INC | $101.10 | 2019 | |
| Vanda Pharmaceuticals INC. | $96.68 | 2019-2020 | |
| Tris Pharma INC | $86.12 | 2019-2020 | |
| Ironshore Pharmaceuticals INC. | $81.73 | 2019 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Avanir Pharmaceuticals, INC. | $71.50 | 2019-2020 | |
| Jazz Pharmaceuticals INC. | $69.70 | 2019-2021 | |
| Rhodes Pharmaceuticals L.P. | $69.42 | 2019 | |
| Arbor Pharmaceuticals, INC. | $46.97 | 2019 | |
| Corium, LLC | $46.29 | 2022-2023 | Azstarys |
| Bausch Health US, LLC | $42.17 | 2020 | |
| Adlon Therapeutics L.P. | $40.10 | 2019 | |
| Indivior INC. | $38.24 | 2019-2023 | Perseris |
| E.R. Squibb & Sons, L.L.C. | $29.39 | 2023-2024 | Camzyos |
| Neos Therapeutics, Lp | $26.36 | 2019 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $15.97 | 2022 | |
| Merck Sharp & Dohme LLC | $14.92 | 2020 | |
| Validus Pharmaceuticals LLC | $11.74 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Wall listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.